A Multicenter, Open-Label, Phase II Study of the 200 Mcg Misoprostol Vaginal Insert (MVI 200) to Obtain Pharmacokinetics in Women at Term Gestation (The MVI-PK Study)
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2014
At a glance
- Drugs Misoprostol (Primary)
- Indications Labour disorders
- Focus Pharmacokinetics
- Acronyms MVI-PK
- Sponsors Ferring Pharmaceuticals
- 26 Aug 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 26 Aug 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
- 26 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.